Monoclonal antibodies against bambi and use thereof for treating inflammatory diseases

Abstract

The invention relates to monoclonal antibodies, in particular against a peptide of the BAMBI protein, as well as the uses thereof and methods comprising same. Preferably, the antibodies are used for the treatment of autoimmune diseases.

1 . A monoclonal antibody that specifically recognizes the sequence SEQ ID NO: 1, or SEQ ID NO: 2. 
     
     
         2 . (canceled) 
     
     
         3 . The antibody according to  claim 1 , wherein the antibody comprises an amino acid heavy chain encoded by the nucleotide sequence that comprises the sequence SEQ ID NO: 3 and an amino acid light chain encoded by the nucleotide sequence that comprises the sequence SEQ ID NO: 4. 
     
     
         4 . The antibody according to  claim 1 , wherein the antibody comprises an amino acid heavy chain encoded by the nucleotide sequence that comprises the sequence SEQ ID NO: 5 and an amino acid light chain encoded by the nucleotide sequence that comprises the sequence SEQ ID NO: 6. 
     
     
         5 . (canceled) 
     
     
         6 . A cell expressing the antibody according to  claim 1 . 
     
     
         7 . An in vitro use of the antibody according to  claim 1  for the inhibition of BMP and Activin Membrane Bound Inhibitor (BAMBI). 
     
     
         8 . The antibody according to  claim 1  for use as a medicament. 
     
     
         9 . The antibody according to  claim 1  for use in the treatment or prevention of autoimmune diseases. 
     
     
         10 . The antibody for use according to  claim 9  wherein the autoimmune diseases are selected from the list consisting of: autoimmune arthritis, spondyloarthritis, psoriasis, systemic lupus erythematosus, and inflammatory bowel disease, preferably wherein the inflammatory bowel disease is ulcerative colitis or Crohn's disease. 
     
     
         11 . (canceled) 
     
     
         12 . A pharmaceutical composition comprising the monoclonal antibody according to  claim 1 . 
     
     
         13 . The in vitro use of the antibody according to  claim 1  for drug screening. 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . A kit and/or device comprising the antibody according to  claim 1 . 
     
     
         19 . (canceled) 
     
     
         20 . The in vitro use of the kit according to  claim 18  for the detection of the sequence SEQ ID NO: 1 or SEQ ID NO: 2. 
     
     
         21 . (canceled) 
     
     
         22 . (canceled) 
     
     
         23 . (canceled)